Zurück zu den Rankings

Balchem Corporation (BCPC)

NEUTRAL
Basic MaterialsSpecialty ChemicalsUnited States

Fundamental

71

Kurs

$179.24

Marktkapitalisierung

$5.79B

Teil 1 · Was das Unternehmen wert ist

Übersicht

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilanz & Liquidität

Umsatz

$1.09B

Letzte 12 Monate (bis 30.6.2026)

Nettogewinn

$164M

Letzte 12 Monate (bis 30.6.2026)

Freier Cashflow

-

Gesamtes Eigenkapital

$1.26B

Gesamtverbindlichkeiten

$429M

Current Ratio

2.66

Zinsdeckungsgrad

-

Schulden/EBITDA

0.65

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

CyclicalÜberbewertet

Innerer Wert

$126.59

Aktueller Kurs

$179.24

Sicherheitsmarge

-41.6%

Innerer-Wert-Spanne

$82.29 - $170.90

Bewertungsmethoden

Analyst price target:$209.25
Discounted cash flow (DCF):Not applicable to this type of company
Earnings multiple (P/E):$139.20
Graham growth formula:Not applicable to this type of company
Earnings power value (EPV):$58.90
Justified P/B:Not applicable to this type of company
Dividend discount (Gordon):Not applicable to this type of company
P/FFO, funds from operations:Not applicable to this type of company
Mid-cycle earnings:$95.30
Revenue multiple:Not applicable to this type of company
Analystenkonsens:Starker Kauf (7B / 2H / 0S)
Letzte Gewinnüberraschung:+4.72%

Bewertungskennzahlen

P/E-Verhältnis

34.87

ROE

12.3%

P/B-Verhältnis

4.34

P/FCF

-

Bruttomarge

36.3%

ROIC

10.9%

Rentabilitäts-Radar

Value Creation (Economic Moat)

ROIC

10.9%

WACC

9.0%

ROIC − WACC

+2.0 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Fundamentalanalyse-Kriterien

Bestanden (17)

  • EPS shows upward trend
  • EPS CAGR 10.73%
  • Price CAGR 8.01%
  • ROIC 11.0%
  • Gross Margin 36.3%
  • Debt/Equity ratio
  • Operating Margin 20.2%
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 12.8%
  • Revenue Growth 5Y 8.1%
  • Analyst Consensus 78% Buy
  • Earnings Quality (OCF/NI) 1.34
  • Share Dilution -0.3%
  • Net Margin Trend 15.1% vs 14.5%
  • Piotroski F-Score 9/9

Nicht bestanden (6)

  • P/B Ratio 4.34
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Earnings Surprise avg 0.9%
  • PEG Ratio 2.72

Nicht verfügbar (5)

  • P/FCF NaN
  • Dividend Payout NaN%
  • Positive Free Cash Flow
  • CapEx intensity
  • Interest Coverage

Piotroski F-Score

9/9

Starke finanzielle Gesundheit

score
criteria

Gewinnqualität

1.34

Hohe Qualität: Gewinne durch Cashflow gedeckt

Aktienverwässerung

-0.3%

Aktienrückkäufe. Aktionärsfreundlich

Unternehmensführung

Führungsteam

NamePositionAlter
Mr. Theodore Lee HarrisCEO, President & Chairman60
Mr. Carl Martin BengtssonExecutive VP, CFO, Treasurer and GM of Animal Nutrition & Health48
Ms. Hatsuki Miyata J.D.Executive VP, Chief Legal Officer & Secretary49
Mr. M. Brent TignorSenior VP & Chief Human Resources Officer47
Mr. Frederic BonedSenior VP, Head of Digital Transformation & AI and GM of Human Nutrition & Health46
Ms. Erin L. GilsonVP & Chief Accounting Officer-
Mr. Martin Luther ReidSenior VP & Chief Supply Chain Officer58
Mr. Job L. van GunsterenSenior VP & GM of Specialty Products48
Mr. George GrahamSenior VP and Chief R&D Officer55

Prüfungsrisiko

3

Vorstandsrisiko

4

Vergütungsrisiko

4

Aktionärsrechterisiko

7

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Latest News

Recent headlines for BCPC, sourced from Markets Gazette.

No recent news for BCPC.